NYU Doctors Explain DCIS

Article

Last month, we got the chance to discuss DCIS with three doctors from NYU Cancer Center: Dr. Deborah Axelrod, Dr. Julia Smith, and Dr. David Kleinberg.

Last month, we got the chance to discuss DCIS with three doctors from NYU Cancer Center: Dr. Deborah Axelrod, Dr. Julia Smith, and Dr. David Kleinberg.

They explain what DCIS is, discuss public trials and future directions for DCIS, and address some current controversies around the diagnosis.

Listen to the talk here:

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Image of a man in a suit smiling in front of an Oncology Nursing News background
Related Content
Graphic of kidneys

Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC

Kyle Doherty
July 1st 2025
Article

ALLO-316 showed significant activity and safety in patients with metastatic CD70-positive clear cell renal cell carcinoma.

The Vitals

What New Cancer Drugs Were Approved in 2023?

Lindsay Fischer
January 1st 2024
Podcast

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Photo of a woman with brown hair and bangs, surrounded by a blue border

AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

Michelle Kirschner, RN, MSN, ACNP, APRN-BC
June 30th 2025
Article

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Graphic of a prostate with a tumor

Retreatment With 177Lu-PSMA-617 May Benefit mCRPC With Sustained Expression

Tim Cortese
June 29th 2025
Article

Patients with metastatic CRPC who maintained PSMA expression had a median OS of 14.5 months with 177Lu-PSMA-617 retreatment.

Graphic of a leukemia cell

FDA Relaxes REMS, Monitoring Rules for Liso-Cel and Ide-Cel

Chris Ryan
June 28th 2025
Article

The FDA removed REMS and reduced certain monitoring needs for liso-cel and ide-cel in B-cell malignancies.